All cause mortality · people with cancer who have febrile neutropenia
beta‐lactam monotherapy showed no clear difference in all cause mortality compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).
1 finding from 1 review
Any nephrotoxicity ‐ Ag dosing regimen (Copy) · people with cancer who have febrile neutropenia
beta‐lactam monotherapy leads to lower any nephrotoxicity ‐ Ag dosing regimen (Copy) compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).
1 finding from 1 review
Clinical failure—same beta lactam Antibiotic modifications · people with cancer who have febrile neutropenia
beta‐lactam monotherapy probably leads to higher treatment failure ‐ same beta‐lactam compared with beta‐lactam‐aminoglycoside combination therapy (moderate certainty).
1 finding from 1 review
Treatment failure ‐ different beta‐lactam · people with cancer who have febrile neutropenia
beta‐lactam monotherapy may leads to lower treatment failure ‐ different beta‐lactam compared with beta‐lactam‐aminoglycoside combination therapy (low certainty).
1 finding from 1 review
All‐cause mortality · people with cancer who have febrile neutropenia
Oral showed no clear difference in mortality compared with intravenous antibiotic therapy (moderate certainty).
1 finding from 1 review
Treatment failure · people with cancer who have febrile neutropenia
Oral showed no clear difference in treatment failure compared with intravenous antibiotic therapy (moderate certainty).
1 finding from 1 review
Treatment failure ‐ per protocol analysis · people with cancer who have febrile neutropenia
Oral showed no clear difference in treatment failure ‐ per protocol analysis compared with intravenous antibiotic therapy (moderate certainty).
1 finding from 1 review
Adverse events requiring discontinuation of antibiotics · people with cancer who have febrile neutropenia
Oral showed no clear difference in adverse events requiring discontinuation of antibiotics compared with intravenous antibiotic therapy (low certainty).
1 finding from 1 review
Treatment failure not dt modification in update · people with cancer who have febrile neutropenia
Oral showed no clear difference in treatment failure not dt modification in update compared with intravenous antibiotic therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).
3 findings from 1 review
RR 1.07 [0.91, 1.25]
4 studies · 541 participants
Moderate
RR 1.06 [0.97, 1.17]
3 studies · 761 participants
Moderate
RR 0.96 [0.65, 1.41]
2 studies · 219 participants
Moderate
3‐year OS · patients with epithelial ovarian cancer
Platin‐based maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).
1 finding from 1 review
5‐year OS · patients with epithelial ovarian cancer
Platin‐based maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).
1 finding from 1 review
10‐year OS · patients with epithelial ovarian cancer
Platin‐based maintenance chemotherapy showed no clear difference in 10‐year OS compared with observation (moderate certainty).
1 finding from 1 review
3‐year OS · patients with epithelial ovarian cancer
Doxorubicin‐based maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).
1 finding from 1 review
5‐year OS · patients with epithelial ovarian cancer
Doxorubicin‐based maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).
1 finding from 1 review
Progression‐free survival · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with maintenance radiotherapy (low certainty).
3 findings from 1 review
RR 1.07 [0.75, 1.54]
1 study · 141 participants
Low
RR 0.86 [0.55, 1.37]
1 study · 141 participants
Low
RR 0.89 [0.51, 1.55]
1 study · 141 participants
Low
3‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
5‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
10‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
3‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).
1 finding from 1 review